BJH - volume 9, issue 2, march 2018
S. Meers MD, PhD
The field of myelodysplastic syndromes has entered the molecular era. New diagnostic tools such as next-generation sequencing are rapidly entering clinical practice and will change the way we diagnose and manage patients with a myelodysplastic syndrome, especially patients considered lower risk by standard diagnostic tools. The treatment of lower risk patients has not changed much since the publication of the BHS recommendations in 2013. However, important trials in lower risk patients have recently been published and will be reviewed here. Finally, the recommendations from an international expert panel for allogeneic transplantation have been published. The key points of this paper will also be discussed as well as results of recently published trials.
(BELG J HEMATOL 2018;9(2):48–56)
Read moreBJH - volume 8, issue 4, august 2017
S. Meers MD, PhD
The past years enormous progress has been made in the understanding of the pathogenesis of myelodysplastic syndromes (MDS).1 The introduction of next-generation sequencing (NGS) and whole-exome sequencing (WES) has revealed that about 90% of patients with MDS harbor mutations in pathways such as spliceosome machinery, in epigenetic regulators and other genes previously unknown to be involved in MDS. At this year’s conference, the focus was on these mutations. There have been no major breakthroughs on the therapeutic side.
(BELG J HEMATOL 2017;8(4):146–8)
Read moreBJH - volume 8, issue Abstract Book BHS, february 2017
B. Malfait MD, J. Braakman , L. de Vos , B. Bailly MD, I. Vande Broek MD, PhD, S. Meers MD, PhD, D. Dierickx MD, PhD
BJH - volume 7, issue Abstract Book BHS, january 2016
B. Devalet , N. Boeckx MD, PhD, B. Chatelain PharmD, C. Chatelain MD, D. Deeren , A. Gothot MD, PhD, S. Meers MD, PhD, T. Devos MD, PhD
BJH - volume 6, issue 2, may 2015
S. Meers MD, PhD, D. Breems MD, PhD, G. Bries MD, PhD, M. Delforge MD, PhD, C. Graux MD, PhD, D. Selleslag MD, L. Noens MD, PhD
The guidelines on the current state-of-the-art in the diagnosis and treatment of myelodysplastic syndromes of the Belgian Hematological Society working group on myelodysplastic syndromes were published in 2013.1 The key points of these guidelines are presented in two issues of the Belgian Journal of Hematology. In this paper we present the optimal treatment of patients with myelodysplastic syndromes within the current limitations of Belgian reimbursement modalities.
(BELG J HEMATOL 2015;6(2):54–60)
Read moreBJH - volume 6, issue 1, march 2015
S. Meers MD, PhD, D. Breems MD, PhD, G. Bries MD, PhD, M. Delforge MD, PhD, C. Graux MD, PhD, D. Selleslag MD, L. Noens MD, PhD
The Belgian Hematological Society working group on myelodysplastic syndromes published their guidelines on the state of the art in diagnosis and treatment of myelodysplastic syndromes and the key points of these recommendations are presented in two issues of the Belgian Journal of Hematology.1 In this first paper we present the requirements for a correct diagnosis and classification of patients with myelodysplasia.
(BELG J HEMATOL 2015;6(1):10–5)
Read moreBJH - volume 5, issue Abstract Book BHS, january 2014
S. Meers MD, PhD, D. Selleslag MD, Y. Beguin MD, PhD, C. Graux MD, PhD, G. Bries MD, PhD, D. Deeren , I. Vrelust MD, P. Pierre , C. Ravoet , K. Theunissen , F. Trullemans , L. Noens MD, PhD, P. Mineur MD
Top
